JP7126514B2 - アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス - Google Patents

アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス Download PDF

Info

Publication number
JP7126514B2
JP7126514B2 JP2019556610A JP2019556610A JP7126514B2 JP 7126514 B2 JP7126514 B2 JP 7126514B2 JP 2019556610 A JP2019556610 A JP 2019556610A JP 2019556610 A JP2019556610 A JP 2019556610A JP 7126514 B2 JP7126514 B2 JP 7126514B2
Authority
JP
Japan
Prior art keywords
mesylate salt
formula
organic solvent
crystalline form
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517611A (ja
JP2020517611A5 (enExample
Inventor
ホ オ，サン
ギュン キム，ジョン
オ，セ－ウォン
ドン ハン，タエ
ヨン チュン，ソ
ラン リー，セオン
バエ キム，キョン
サン リー，ヨン
ソブ シン，ウォ
ジュ，ヒュン
キ カン，ジョン
ミン パーク，ス
キュン キム，ドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63857137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7126514(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of JP2020517611A publication Critical patent/JP2020517611A/ja
Publication of JP2020517611A5 publication Critical patent/JP2020517611A5/ja
Priority to JP2022129468A priority Critical patent/JP7390444B2/ja
Application granted granted Critical
Publication of JP7126514B2 publication Critical patent/JP7126514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019556610A 2017-04-21 2018-04-18 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス Active JP7126514B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022129468A JP7390444B2 (ja) 2017-04-21 2022-08-16 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0051687 2017-04-21
KR20170051687 2017-04-21
PCT/KR2018/004473 WO2018194356A1 (en) 2017-04-21 2018-04-18 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022129468A Division JP7390444B2 (ja) 2017-04-21 2022-08-16 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス

Publications (3)

Publication Number Publication Date
JP2020517611A JP2020517611A (ja) 2020-06-18
JP2020517611A5 JP2020517611A5 (enExample) 2021-04-30
JP7126514B2 true JP7126514B2 (ja) 2022-08-26

Family

ID=63857137

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556610A Active JP7126514B2 (ja) 2017-04-21 2018-04-18 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス
JP2022129468A Active JP7390444B2 (ja) 2017-04-21 2022-08-16 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022129468A Active JP7390444B2 (ja) 2017-04-21 2022-08-16 アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス

Country Status (23)

Country Link
US (3) US11453656B2 (enExample)
EP (1) EP3612529A4 (enExample)
JP (2) JP7126514B2 (enExample)
KR (3) KR102629654B1 (enExample)
CN (1) CN110869367B (enExample)
AR (1) AR111469A1 (enExample)
AU (2) AU2018256227B2 (enExample)
BR (1) BR112019021868A2 (enExample)
CA (1) CA3059543A1 (enExample)
CO (1) CO2019011578A2 (enExample)
EA (1) EA201992501A1 (enExample)
IL (2) IL294666B2 (enExample)
MA (1) MA49696A (enExample)
MX (2) MX392634B (enExample)
MY (1) MY201919A (enExample)
NZ (1) NZ758443A (enExample)
PH (1) PH12019502370A1 (enExample)
SA (1) SA519410342B1 (enExample)
SG (1) SG11201909615YA (enExample)
TW (1) TWI776882B (enExample)
UA (1) UA124364C2 (enExample)
WO (1) WO2018194356A1 (enExample)
ZA (1) ZA201907687B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022166179A (ja) * 2017-04-21 2022-11-01 ユハン コーポレーション アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3658552T2 (ro) 2017-07-28 2024-02-29 Yuhan Corp Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
EP3885346A4 (en) * 2018-12-21 2022-01-12 Shenzhen TargetRx, Inc. Aminopyrimidine compound used for inhibiting activity of protein kinase
EP3931224A4 (en) 2019-02-26 2023-03-01 Janssen Biotech, Inc. COMBINATION TREATMENTS AND PATIENT STRATIFICATION WITH ANTI-EGFR/C-MET BISPECIFIC ANTIBODIES
MX2021013955A (es) * 2019-05-14 2022-03-11 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación.
WO2020230091A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
WO2022253261A1 (zh) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech Inc Methods for treatment of non-small cell lung cancer (nsclc)
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016060443A2 (en) 2014-10-13 2016-04-21 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063713A1 (ja) 2003-12-25 2005-07-14 Eisai Co., Ltd. ４−（３−クロロ−４−（シクロプロピルアミノカルボニル）アミノフェノキシ）−７−メトキシ−６−キノリンカルボキサミドの塩またはその溶媒和物の結晶およびそれらの製造方法
CA2555804C (en) 2004-02-11 2012-06-26 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
NZ624345A (en) * 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
EP2498607B1 (en) * 2009-11-13 2016-02-17 Genosco Kinase inhibitors
EP2649060B1 (en) * 2010-12-06 2017-04-05 MSN Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
EP3333161B1 (en) 2011-07-27 2020-02-19 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
CN104540822B (zh) 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
CN106687457B (zh) 2014-05-13 2020-01-10 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
KR101794186B1 (ko) 2015-10-30 2017-11-08 한국기술교육대학교 산학협력단 전기자동차용 급전장치
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016060443A2 (en) 2014-10-13 2016-04-21 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022166179A (ja) * 2017-04-21 2022-11-01 ユハン コーポレーション アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス
JP7390444B2 (ja) 2017-04-21 2023-12-01 ユハン コーポレーション アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス
US12428401B2 (en) 2017-04-21 2025-09-30 Yuhan Corporation Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Also Published As

Publication number Publication date
ZA201907687B (en) 2023-04-26
KR20180118535A (ko) 2018-10-31
AR111469A1 (es) 2019-07-17
WO2018194356A1 (en) 2018-10-25
US20210139461A1 (en) 2021-05-13
US11453656B2 (en) 2022-09-27
TW201841910A (zh) 2018-12-01
IL270018A (enExample) 2019-12-31
AU2018256227B2 (en) 2022-03-03
EP3612529A4 (en) 2020-11-18
AU2018256227A1 (en) 2019-10-31
EA201992501A1 (ru) 2020-02-18
US12428401B2 (en) 2025-09-30
CA3059543A1 (en) 2018-10-25
PH12019502370A1 (en) 2020-07-13
UA124364C2 (uk) 2021-09-01
KR20230175161A (ko) 2023-12-29
JP2020517611A (ja) 2020-06-18
MY201919A (en) 2024-03-23
MX2022006357A (es) 2022-06-23
US20230021395A1 (en) 2023-01-26
AU2022203486A1 (en) 2022-06-09
JP7390444B2 (ja) 2023-12-01
TWI776882B (zh) 2022-09-11
US20240279203A1 (en) 2024-08-22
IL294666B1 (en) 2024-01-01
CN110869367A (zh) 2020-03-06
AU2022203486B2 (en) 2024-06-06
IL294666B2 (en) 2024-05-01
SG11201909615YA (en) 2019-11-28
KR102835717B1 (ko) 2025-07-18
KR102629654B1 (ko) 2024-01-29
IL294666A (en) 2022-09-01
JP2022166179A (ja) 2022-11-01
CO2019011578A2 (es) 2020-02-28
US11981659B2 (en) 2024-05-14
MA49696A (fr) 2020-06-03
BR112019021868A2 (pt) 2020-05-26
SA519410342B1 (ar) 2023-02-09
EP3612529A1 (en) 2020-02-26
NZ758443A (en) 2023-03-31
KR20250111074A (ko) 2025-07-22
CN110869367B (zh) 2023-09-15
MX392634B (es) 2025-03-24
IL270018B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
JP7390444B2 (ja) アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス
KR102662358B1 (ko) Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
JP7369769B2 (ja) アミノピリミジン誘導体又はその塩を含む経口投与用医薬組成物
US9388165B2 (en) Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase
JP2019507776A (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
KR20230163335A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
KR101929725B1 (ko) 의학적 적용을 위한 3-(1,2,4-트리아졸로[4,3-a]피리딘-3-일에티닐)-4-메틸-N-(4-((4-메틸피페라진-1-일)메틸)-3-트리플루오로메틸페닐)벤즈아미드의 신규 결정질 염 형태
HK40025158A (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
HK40025158B (zh) 氨基吡啶衍生物化合物的盐、其结晶形式、以及用於制备它们的方法
CN117396463A (zh) 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法和含有其作为活性成分的药物组合物
KR102382641B1 (ko) 신규한 tyro 3 저해 화합물, 이의 제조방법, 및 이를 유효성분으로 함유하는 tyro 3 관련 질환의 예방 또는 치료용 약학적 조성물
EA041089B1 (ru) Соль соединения производного аминопиридина, ее кристаллическая форма и способ получения
WO2010083649A1 (zh) 双芳基脲类衍生物及用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220726

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220816

R150 Certificate of patent or registration of utility model

Ref document number: 7126514

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250